A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants.

BioRxiv : the Preprint Server for Biology
Aaron J SchmitzAli H Ellebedy

Abstract

The emergence of antigenically distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increased transmissibility is a public health threat. Some of these variants show substantial resistance to neutralization by SARS-CoV-2 infection- or vaccination-induced antibodies, which principally target the receptor binding domain (RBD) on the virus spike glycoprotein. Here, we describe 2C08, a SARS-CoV-2 mRNA vaccine-induced germinal center B cell-derived human monoclonal antibody that binds to the receptor binding motif within the RBD. 2C08 broadly neutralizes SARS-CoV-2 variants with remarkable potency and reduces lung inflammation, viral load, and morbidity in hamsters challenged with either an ancestral SARS-CoV-2 strain or a recent variant of concern. Clonal analysis identified 2C08-like public clonotypes among B cell clones responding to SARS-CoV-2 infection or vaccination in at least 20 out of 78 individuals. Thus, 2C08-like antibodies can be readily induced by SARS-CoV-2 vaccines and mitigate resistance by circulating variants of concern. Protection against SARS-CoV-2 variants by a potently neutralizing vaccine-induced human monoclonal antibody.

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Related Papers

BioRxiv : the Preprint Server for Biology
Yiska WeisblumPaul D Bieniasz
BioRxiv : the Preprint Server for Biology
Yiska WeisblumPaul D Bieniasz
BioRxiv : the Preprint Server for Biology
K. GuoMario L Santiago
© 2021 Meta ULC. All rights reserved